
    
      This is a Phase III randomized, double-blind, parallel group, multi-center, 52-week COPD
      exacerbation and lung function study. Subjects will undergo a 1- to 4-week Screening Period.
      Subjects who successfully complete the Screening Period will be randomized to one of the
      following three treatment groups: PT009 320/9.6 μg, PT009 160/9.6 μg and PT005 9.6 μg, all
      administered BID. Following randomization, subjects will enter the Treatment Period and
      undergo additional treatment visits over 52 weeks.
    
  